LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

Search

IQVIA Holdings Inc

Abrir

SetorSaúde

152.82 0.28

Visão Geral

Variação de preço das ações

24h

Atual

Mín

151.54

Máximo

156.38

Indicadores-chave

By Trading Economics

Rendimento

152M

437M

Vendas

58M

4B

P/E

Médio do Setor

20.491

54.379

EPS

3.12

Margem de lucro

11.041

Funcionários

88,000

EBITDA

165M

1B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+26.23% upside

Dividendos

By Dow Jones

Próximos Ganhos

21 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-9.5B

27B

Abertura anterior

152.54

Fecho anterior

152.82

Sentimento de Notícias

By Acuity

10%

90%

4 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

IQVIA Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de mai. de 2025, 23:59 UTC

Principais Notícias
Ganhos

Naver 1Q Net Slumps on Higher Costs

8 de mai. de 2025, 23:39 UTC

Ganhos

OCBC 1Q Net Down on Lower Interest Income

8 de mai. de 2025, 23:01 UTC

Ganhos

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 de mai. de 2025, 22:52 UTC

Ganhos

REA Expects Annual Listings Growth Despite April Decline

8 de mai. de 2025, 22:46 UTC

Ganhos

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 de mai. de 2025, 23:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de mai. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 de mai. de 2025, 23:41 UTC

Conversa de Mercado

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 de mai. de 2025, 23:30 UTC

Ganhos

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 de mai. de 2025, 23:29 UTC

Ganhos

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 de mai. de 2025, 23:22 UTC

Ganhos

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 de mai. de 2025, 23:22 UTC

Ganhos

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 de mai. de 2025, 23:21 UTC

Ganhos

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 de mai. de 2025, 23:21 UTC

Ganhos

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 de mai. de 2025, 23:17 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 de mai. de 2025, 23:17 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 de mai. de 2025, 23:17 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 de mai. de 2025, 23:05 UTC

Conversa de Mercado

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 de mai. de 2025, 23:05 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de mai. de 2025, 23:01 UTC

Principais Notícias

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 de mai. de 2025, 22:28 UTC

Ganhos

REA Expects FY 2025 Listings Growth of 1-2%

8 de mai. de 2025, 22:28 UTC

Ganhos

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 de mai. de 2025, 22:27 UTC

Ganhos

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 de mai. de 2025, 22:27 UTC

Ganhos

REA Says April Residential Listings Fell by 11% on Year

8 de mai. de 2025, 22:26 UTC

Ganhos

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 de mai. de 2025, 22:26 UTC

Ganhos

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 de mai. de 2025, 22:26 UTC

Ganhos

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 de mai. de 2025, 22:26 UTC

Ganhos

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 de mai. de 2025, 22:25 UTC

Ganhos

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 de mai. de 2025, 22:25 UTC

Ganhos

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Comparação entre Pares

Variação de preço

IQVIA Holdings Inc Previsão

Preço-alvo

By TipRanks

26.23% parte superior

Previsão para 12 meses

Média 193.5 USD  26.23%

Máximo 270 USD

Mínimo 160 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para IQVIA Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

17 ratings

12

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

150.68 / 153.45Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

4 / 382 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.